“One person undergoing tests for an abdominal and pelvic mass said CT and MRI scans, with and without contrast, cost 210 million rials ($113) despite having Social Security insurance.”
By Hooman Abedi – Iran International
Iranians are struggling to afford medicines and medical care, with some foregoing treatment as prices rise, drug shortages spread and insurance coverage falls short, according to accounts from patients.
Messages sent to Iran International on described medical bills consuming much or all of a typical monthly income, even for people covered by Iran’s Social Security Organization, the country’s main state-run social insurer.
One person undergoing tests for an abdominal and pelvic mass said CT and MRI scans, with and without contrast, cost 210 million rials ($113) despite having Social Security insurance.
“How are we supposed to pay these costs with such meager incomes?” the citizen said.
Many Iranian workers earn around 200 million to 250 million rials ($108-$134) a month, meaning the scans alone can cost roughly a month’s income. The rial trades at around 1.86 million to the dollar on the free market.
Another said an echocardiogram, electrocardiogram and clinic appointment cost 120 million rials ($65), with the medical provider requiring payment upfront rather than accepting Social Security insurance.
The patient was given documents to seek reimbursement from the insurer but said the process involved extensive bureaucracy and could result in only around half the money being returned.
A 33-year-old said the cost of dental treatment had left him without half his teeth.
“I feel like I’m 60,” he said. “The bitter part is that this humiliating way of life has become normal for me.”
Another worker earning 10 million rials ($5.40) a day said an appointment with an ear, nose and throat doctor cost 5 million rials ($2.70), followed by 8.6 million rials ($4.60) for medicine.
“We really cannot afford to live anymore,” the worker said.
Lawmaker says shortages could worsen
The accounts echo comments from Salman Es’haghi, spokesman for parliament’s Health and Treatment Committee, who said shortages and rising prices were already causing some patients to stop treatment.
Around 43 medicines are in “critical shortage” and nearly 1,000 pharmaceutical products face some degree of shortage, Es’haghi told the Tabnak news website in an interview published Saturday.
Prices for chemotherapy drugs and medicines used by patients with cancer, hemophilia and thalassemia have risen enough to reduce consumption, with some patients stopping treatment because they cannot afford it, he said.
Es’haghi said patients now pay more than 70% of their healthcare expenses themselves, despite policies intended to leave individuals covering around 30% and the government and insurers paying the remainder.
Some hospitals and pharmacies are also refusing to provide certain services or medicines because insurers have delayed reimbursements or failed to pay them in full, he added.
The difficulties described by Iran International’s audience reflected those problems. One viewer said a packet of Sertraline tablets that previously cost 500,000 rials had risen to 8 million rials, a sixteen-fold increase.
Another said the cost of healthcare had left the family worried about something as routine as a child catching a cold during the winter.
“We’re stressed about where we would get the money for treatment if, God forbid, we or our children even catch a cold,” the audience said.
Drug subsidy faces uncertain future
The pressure could intensify if the government removes preferential foreign currency for medicines and medical equipment from the budget for the Iranian year beginning in March 2027, Es’haghi warned.
Iran has used preferential exchange rates to lower the rial cost of importing medicines, pharmaceutical ingredients and medical supplies. Removing that support can expose producers and importers to much higher exchange rates and ultimately increase prices for patients.
Discussions about eliminating the preferential rate have been under way since late 2025, with the government viewing the change as a possible way to address corruption and preferential access to subsidized foreign currency, Es’haghi said.
“If the currency allocated to medicines and medical equipment is removed from next year’s budget, it could become a ‘year of patient slaughter,’” Es’haghi said.
Iran International reported in April that prices for some domestically produced insulin had risen by as much as 212% compared with before the Persian New Year in March, while some imported varieties had increased by as much as 271%.
Pharmaceutical industry figures have attributed rising production costs to a combination of exchange-rate changes, the rial’s depreciation, more expensive raw materials and packaging, higher wages and financing costs, and disruption to supply chains from war.
Es’haghi said more than 70% of medicines had increased in price and argued that authorities should tackle corruption through closer oversight of the pharmaceutical supply chain rather than eliminating subsidized currency.
For patients confronting medical bills comparable to their monthly earnings, however, the pressure is already being measured in delayed care, abandoned treatment and anxiety over whether they can afford the next illness.